Motamed Cancer Institute- Recombinant Proteins in Cancer

Clear images and colors  | Post date: 2017/11/12 | 
  1. Mansouri S, Farahmand L, Teymourzadeh A, Majidzadeh AK. Clinical evidence on the magnitude of change in growth pathway activity in relation to Tamoxifen resistance is required. Current cancer drug targets. (Future Oncol2017).
  2.   Mansouri S, Farahmand L, Hosseinzade A, Eslami SZ, Majidzadeh AK. Estrogen can restore Tamoxifen sensitivity in breast cancer cells amidst the complex network of resistance. (Biomedicine & Pharmacotherapy 93 (2017) 1320–1325).
  3. Darvishi B, Farahmand L, Eslami SZ, Majidzadeh AK. NF-kappaB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer. (Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2017;39(6):1010428317706919.)
  4. Darvishi B, Farahmand L, Majidzadeh AK. Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.( Molecular therapy Nucleic acids. 2017;7:164-80.)
  5.   Merikhian P, Ghadirian R, Farahmand L, Mansouri S, Majidzadeh AK. MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer.( Expert review of anticancer therapy. 2017;17(7):607-13.)
  6. Teymourzadeh A, Mansouri S, Farahmand L, Hosseinzade A, Majidzadeh AK. ER-alpha36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance. . (Clinical Breast Cancer (2017), doi: 10.1016/j.clbc.2017.03.013)
  7. Darvishi B, Farahmand L, Majidzadeh AK. Patterns of Cancer Stem Cell Negotiation with Breast Cancer Anti-angiogenic Therapy. (The Breast Journal, 2017 1–3.)
  8. Estiar MA, Zare AA, Esmaeili R, Farahmand L, Fazilaty H, Jafari D, et al. Clinical significance of NDRG3 in patients with breast cancer.( Future oncology. 2017;13(11):961-9.
  9. Mansouri S, Naghavi-Al-Hosseini F, Farahmand L, Majidzadeh AK. MED1 may explain the interaction between receptor tyrosine kinases and ERalpha66 in the complicated network of Tamoxifen resistance. (European journal of pharmacology. 2017;804:78-81.)
  10. Madjid Ansari A, Majidzadeh AK, Darvishi B, Sanati H, Farahmand L, Norouzian D. Extremely low frequency magnetic field enhances glucose oxidase expression in Pichia pastoris GS115.( Enzyme and microbial technology. 2017;98:67-75.)
  11. . Farahmand L, Darvishi B, Majidzadeh AK, Madjid Ansari A. Naturally occurring compounds acting as potent anti-metastatic agents and their suppressing effects on Hedgehog and WNT/beta-catenin signalling pathways.( Cell proliferation. 2017;50(1).)
  12. Farahmand L, Darvishi B, Majidzadeh-A K,. Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides(.Drug Deliv. 2017 Nov;24(1):1249-1261.)
  13. Mahsa Bakhtiari, Yunes Panahi, Javad Ameli, Behrad Darvishi Protective effects of flavonoids against Alzheimer’s disease-related neural dysfunctions. (Biomedicine & Pharmacotherapy 93 (2017) 218–229).
  14. Fatemeh Beiraghdar, Behzad Einollahi, Alireza Ghadyani, Yunes Panahi, Abbas Hadjiakhoondib, Mahdi Vazirian, Ali Salarytabar and Behrad Darvishi, A two-week, double-blind, placebo-controlled trial of Viola odorata, Echium amoenum and Physalis alkekengi mixture in symptomatic benign prostate hyperplasia (BPH) men( .PHARMACEUTICAL BIOLOGY, .( 2017) VOL. 55, NO. 1, 1800–1805).
  15. Estiar MA, Esmaeili R, Zare AA, Farahmand L, Fazilaty H, Zekri A, et al. High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer.( Clinical and experimental medicine. 2016).
  16. Darvishi B, Farahmand L, Jalili N, Majidzadeh AK. Blinatumomab provoked fatal heart failure.( International immunopharmacology. 2016;41:42-6.)
Topic URL in Motamed Cancer Institute website:
Back to content primary page